Skip to main content
. 2017 Sep 18;8(58):98163–98183. doi: 10.18632/oncotarget.21000

Figure 2. The treatment with cyclophosphamide caused severe bone loss in mice.

Figure 2

(A) Male C57BL/6 mice were administered with saline or cyclophosphamide (CPD, 100mg/kg/days (d)) for 7 consecutive days by intraperitoneal injections. The mice were maintained for additional 3,7and 12 days before harvesting. Micro-CT analysis was performed on lumbar vertebrate (LV1~3) and one representative imagine from each group was shown. (B) The bone parameters were shown as the following: Bone mineral density (BMD); Connectivity density (Conn. D); Bone volume over total volume (BV/TV); Trabecular bone number (Tb.N); Trabecular bone separation (Tb. Sp); Trabecular bone thickness (Tb. Th). (C) H&E stains were performed on LV1~3. (D) One representative image on the proximal metaphysis of tibia was shown. (E) The bone parameters were shown as the following: Bone mineral density (BMD); Connectivitydensity (Conn. D); Bone volume over total volume (BV/TV); Trabecular bone number (Tb. N); Trabecular bone separation (Tb. Sp); Trabecular bone thickness (Tb. Th). (F) H&E stains were performed on tibias. Values were expressed as means ± SEM. * P < 0.05, #P < 0.01, vs. Saline control group at the same time point.